"Rank","NCT Number","Title","Acronym","Status","Study Results","Conditions","Interventions","Outcome Measures","Sponsor/Collaborators","Gender","Age","Phases","Enrollment","Funded Bys","Study Type","Study Designs","Other IDs","Start Date","Primary Completion Date","Completion Date","First Posted","Results First Posted","Last Update Posted","Locations","Study Documents","URL"
1,"NCT01331642","Biomarker for Gaucher Disease","BIOGAUCHER","Recruiting","No Results Available","Splenomegaly|Hepatomegaly|Anemia or Thrombocytopenia","","Sequencing of the Gaucher disease related gene|The Gaucher disease specific biomarker candidates finding","Centogene AG Rostock","All","Child, Adult, Older Adult","","1000","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","BG 06-2018","August 20, 2018","June 2021","June 2021","April 8, 2011","null","January 24, 2019","Health Technology Assessment in Clinical Genetics Research Group, Porto Alegre, Brazil|Clinics Hospital of Ribeirao Preto- University of Sao Paulo, Sao Paulo, Brazil|Children Hospital, Faculty of Medicine, Cairo University, Cairo, Egypt|Centogene AG, Rostock, Germany|Aristotle University of Thessaloniki-Ippokration General Hospital, Thessaloniki, Greece|Amrita Institute of Medical Sciences & Research Centre, Cochin, Kerala, India|Navi Mumbai Institute of Research In Mental And Neurological Handicap (NIRMAN), Mumbai, India|Mother and Child Health Institute of Serbia, Novi-Beograd, Serbia","","https://ClinicalTrials.gov/show/NCT01331642"
2,"NCT03523117","Multicenter Randomized Active-controlled Study to Investigate Efficacy & Safety of IV FCM in Pediatric Patients With IDA",,"Recruiting","No Results Available","Iron Deficiency Anemia","Drug: Ferric carboxymaltose|Drug: Ferrous Sulfate","Change in hemoglobin|Change in ferritin|Change in TSAT|Change in reticulocyte hemoglobin content","American Regent, Inc.","All","1 Year to 17 Years Â  (Child)","Phase 3","72","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1VIT17044","September 12, 2018","January 2020","January 2021","May 14, 2018","null","December 13, 2018","Arkansas Children's Hospital, Little Rock, Arkansas, United States|International Research Partners, Inc., Doral, Florida, United States|South Florida Research Phase I-IV, Miami Springs, Florida, United States|Riley Hospital for Children,Room 4340, Indianapolis, Indiana, United States|Caro Health Plaza, Caro, Michigan, United States|Cincinnati Children's Hospital and Medical Center, Cincinnati, Ohio, United States|Baylor College of Medicine/Texas Children Hospital, Houston, Texas, United States|Tekton Research, San Antonio, Texas, United States|Aspen Clinical Research, Orem, Utah, United States","","https://ClinicalTrials.gov/show/NCT03523117"
